Read the latest update on ON Helix 2024 here
The Life Sciences Catalyst Business Lounge, designed to be a regional hotspot for start-ups and world-leading businesses in the life sciences sector, has been opened by Deloitte Cambridge.
The Life Sciences Catalyst Business Lounge is based within Deloitte Cambridge’s existing office and located on the 1st floor.
The 1,152 sq. ft lounge comprises a mix of formal and informal meeting areas across three zones – a touchdown zone, which provides a comfortable and casual space for members to work; a collaboration zone - perfect for group discussions and brainstorming sessions and, the executive…
• Company will host a CEO and key opinion leader webinar at 14.30 BST• AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI• Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI• Enables delivery of a highly concentrated, low volume injection, offering more effective mealtime glucose control to meet growing unmet need in patients requiring high daily doses…
New drug discovery platform integrates computational approaches with molecular biology for development of novel degrader therapeutics
Cambridge, UK, 21 May 2024: PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™. The new phenotypic screening platform expands the Company’s capabilities in this emerging therapeutic modality to support the systematic discovery and development of novel molecular glue degraders (MGDs) for targeted protein degradation (TPD).
MGDs are an important new class of small…
Arecor Therapeutics plc
(“Arecor” or “the Company”)
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES
• AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI
• Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI
• Enables delivery of a highly concentrated…
Lehane Consulting Ltd are celebrating our 1 year anniversary! We launched our services in 2023 and have enjoyed a fantastic first year of building our network, sharing our skills and welcoming new customers. To mark our birthday in style, we would like to offer One Nucleus members the opportunity for a 20 minute introductory call - to meet, engage and explore the potential of new projects in 2024.
Drop an email to Lucy@Lehaneconsulting.co.uk quoting #YearOneNucleus
About Lehane Consulting Ltd
With over 25 years' of expertise in the IVD Industry, we are dedicated to helping…
We are delighted to share the results from Aon's 2023 Global Risk Management Survey (GRMS).
The GRMS collects and analyses business leaders' assessment of risk and risk management. The 2023 report is the ninth edition of the survey and the results from both Global and UK respondents reflect the increasingly interconnected nature of risk, with traditional business risks and people risks converging to create significant challenges for organisations.
GRMS survey findings for the Life Sciences industry ranked supply chain or distribution failure, and cyber-attack or data breach as their two most…
Delivery across the business leaves Arecor in strong position
Continued momentum in diabetes portfolio with AT278 clinical trial on track for key data readout in H1 2024
First commercial launch of Arestat™ enabled product licensed to partner, AT220, triggering milestone payment and now generating royalties
Further expansion of partnership portfolio and licensing of products incorporating Arestat™ technology
Continued success of Ogluo® commercialisation increasing Tetris Pharma product sales to £2.9 million (2022: £1.1 million)
Total Group revenue of £4.6 million (2022: £2.4…
Aon – Life Science Sector Specific Employee Benefits Survey:
Participating in this targeted survey can give you unique data insight to help:
Benchmark against your industry and non-industry competition to support attraction and retention of talent.
Create a business case backed by data to justify positive benefit changes in your organisation.
Why should organisations participate in this survey?
Aon’s Life Science specific benefits benchmarking survey provides a unique opportunity for organisations to use our data insights to understand how they measure up to their competitors…
The Cambridge Wide Open Day event on Wednesday 12th June is a unique opportunity for all to find out firsthand about the game-changing scientific advancements and technological innovations happening right here in our city, the UK’s science and tech capital.
The cream of Cambridge science and technology is opening its doors to participate in this year’s Be Curious event across the four main science clusters located in:
· Cambridge North including Allia Future Business Kings Edge, Cambridge Science Park, St John’s Innovation Centre, Co-Laboratories, and…